Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study - Report - MDSpire

Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study

  • By

  • Jiseung Kang

  • Hyeon Jin Kim

  • Min Seo Kim

  • Jae Il Shin

  • Dong Keon Yon

  • June 16, 2026

  • 0 min

Share

Correction Notice: Global Impact of Substance Consumption 1990-2023

Overview

This correction notice addresses errors in the Competing Interests statements of several authors from the GBD 2023 Substance Use Collaborators. Nine authors had their statements amended to accurately reflect their financial disclosures related to the manuscript.

Background

Accurate reporting of competing interests is crucial in research to maintain transparency and integrity. This correction highlights the importance of thorough review processes in scholarly publications, particularly in studies assessing global substance use trends.

Data Highlights

No numerical or trial data is presented in this correction notice.

Key Findings

  • Errors and omissions were identified in the Competing Interests statements of nine authors.
  • Competing interests for S. Afzal and L. Monasta were amended to include relevant grants and support.
  • Corrections were made to J.P.S. and L.M.L.R.S. regarding their funding sources.
  • Competing interests statements for B. Oancea, K. Krishan, and I. N. Soyiri were added after being omitted in the original publication.
  • The NIH grant number for A.C.T. was corrected from K34DA061696 to K24DA061696.

Clinical Implications

Researchers and healthcare professionals should ensure that all competing interests are disclosed to uphold the integrity of scientific literature. This correction serves as a reminder of the importance of transparency in research funding.

Conclusion

The corrections made to the Competing Interests statements reinforce the necessity for accuracy in scholarly communications. No other parts of the article have been altered.

Related Resources & Content

  1. Nature Medicine, 2026 -- Correction Notice: Assessment of the Global Impact of Amphetamine, Cannabis, Cocaine, and Opioid Consumption Across 204 Nations from 1990 to 2023
  2. Frontiers in Psychiatry — Trends of incident stimulant use disorder diagnoses before and after the COVID-19 pandemic in British Columbia (2013-2024): a population-based study
  3. BMC Psychiatry (Springer) — Cortical morphological alterations in methamphetamine-induced psychosis: a surface-based morphometry study
  4. Archives of Toxicology — The landscape of cocaine cytotoxicity and the role of sigma-1 receptor modulation and adulterant synergism
  5. American Journal of Epidemiology — Impact of Prescription Opioid and Cannabis Regulation on Opioid Overdose Mortality Rates
  6. WHO updates guidelines on opioid dependence treatment and overdose prevention
  7. Medications for Opioid Use Disorder | SAMHSA
  8. DEA and HHS Issue Final Telemedicine Rule for Buprenorphine Access | SAMHSA
  9. Lifesaving Naloxone | Stop Overdose | CDC
  10. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder - PMC
  11. Contingency Management for Stimulant Use Disorder and Association With Mortality: A Cohort Study | American Journal of Psychiatry
  12. Checking your browser - reCAPTCHA
  13. Cannabis Use During Pregnancy and Lactation | ACOG
  14. Brief Drug Interventions Delivered in General Medical Settings: a Systematic Review and Meta-analysis of Cannabis Use Outcomes | Prevention Science | Springer Nature Link
  15. Cannabis Effective January 28, 2025 TABLE OF CON

Original Source(s)

Related Content